Verrupatch 3,75 mg parches cutaneos

Leaflet: information for the user

Verrupatch 3.75mg skin patches

salicylic acid

Contents of the leaflet

1. What Verrupatch is and what it is used for
2. What you need to know before using Verrupatch
3. How to use Verrupatch
4. Possible side effects
5. Storage of Verrupatch
6. Contents of the package and additional information

Verrupatch is a medication in the form of skin patches and belongs to the group of antiverruga medications.

It contains salicylic acid as the active ingredient, with antiverruga properties due to its keratolytic activity, which produces softening and subsequent destruction of the stratum corneum, allowing for the elimination of warts.

Verrupatch is indicated for the local treatment of common warts, which usually appear on the hands or feet (plantar warts).

Do not use Verrupatch

• If you are allergic to salicylic acid or any of the other components of this medication (listed in section 6).
• Do not apply on moles, birthmarks, hairy warts, genital warts, facial warts, or mucous membranes.
• Do not use this product on irritated or wounded skin or on any area that is infected, inflamed, or red.
• Do not use in children under 2 years old.

Warnings and Precautions

Consult your doctor or pharmacist before starting to use Verrupatch.

Do not ingest. Use only on the skin.

Avoid contact with healthy skin.

Avoid contact with the eyes.

In case of accidental application in the eyes, rinse with plenty of water.

People with diabetes or poor circulation should consult their doctor before using this medication.

Children

Do not use in children between 2 and 12 years old without consulting a doctor (SeeDo not use Verrupatch).

Children may be at a higher risk of adverse effects.

Other medications and Verrupatch

Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication.

Do not use this medicationwith otherkeratolytics(wart removers) in the same area, as they may enhance its effect.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.

Do not use Verrupatch during pregnancy, except for the short-term treatment of a small wart.

Oral forms (e.g., tablets) of this type of medication may cause adverse effects on the fetus. It is unknown if the same risks apply to Verrupatch when used on warts.

Decide whether to interrupt breastfeeding or interrupt treatment, considering the benefits of breastfeeding for the child and the benefits of treatment for the mother.

Driving and operating machinery

The influence of Verrupatch on the ability to drive and operate machinery is negligible or insignificant.

Verrupatch contains propylene glycol (E-1520)

This medication contains 11.25 mg of propylene glycol in each dosage unit (patch).

Propylene glycol may cause skin irritation.

Follow exactly the administration instructions of the medication contained in this leaflet or those indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.

Cutaneous use (on the skin).

The recommended dose is a Verrupatch patch once a day, preferably before going to bed.

Use in children

Do not use in children under 2 years old.

In children under 12 years old and over 2 years old, do not use without consulting a doctor and avoid prolonged use in children.

Instructions for correct administration

Leave the patch to act overnight (about 8 hours) and remove it in the morning. Repeat this process daily, for a maximum of 12 weeks, until the wart is eliminated. Generally, noticeable improvement occurs within the first few days, and complete resolution can be expected within 3 to 6 weeks of treatment.

Consult your doctor or pharmacist if you do not notice improvement after 1 week, or if warts are abundant or if infection or inflammation occurs.

If you use more Verrupatch than you should

No cases of overdose are expected due to the mode of application of this medication. Excessive use may cause irritation, especially on healthy skin. Use emollients if necessary.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call a medical center or contact the Toxicological Information Service, Teléfono 91 562 04 20, indicating the medication and the amount used.

If you forgot to use Verrupatch

Do not apply a double dose to compensate for the missed dose. Apply the product again at your usual time.

If you interrupt treatment with Verrupatch

If you have any other questions about the use of this medication, ask your doctor or pharmacist..

Like all medications, this medication may produce adverse effects, although not everyone may experience them.

Irritation may occur if the patches come into contact with healthy skin surrounding the wart. In this case, it is recommended to temporarily suspend treatment until the irritation disappears. When resuming treatment, special attention should be paid to ensuring the patch is properly cut, so that it only comes into contact with the wart tissue.

Excessive peeling has been reported in open wounds; also, serious allergic reactions.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through theSpanish System for Pharmacovigilance of Medicinal Products for Human Use:www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.

Keep this medication out of the sight and reach of children.

No special storage conditions are required.

Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.

Do not use this medication if you observe visible signs of deterioration in the appearance of the skin patches.

Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.

Composition of Verrupatch

- The active ingredient is salicylic acid. Each patch contains 3.75mg of salicylic acid.

- The other components (excipients) are: propylene glycol (E-1520), karaya gum, polyethylene glycol 300 (Macrogol 300) and quaternium-15.

Appearance of the product and contents of the packaging

Verrupatch is presented in the form of circular, cutaneous patches, 6mmin diameter, beige in color, and covered with a blue layer of polyethylene that retains moisture, exerting an occlusive effect.

Each package contains 20patches arranged in two moisture-resistant, hermetic pouches, with 10patches in each one.

To fix the patches in the correct position, 20 dermocompatible adhesive strips are incorporated. A file is also provided to remove any remaining residue from the surface of the wart.

Marketing Authorization Holder

Laboratorios Viñas, S.A.

Provenza, 386

08025 - Barcelona

Spain

Responsible for Manufacturing

Laboratorios Viñas, S.A.

Torrente Vidalet, 29

08012- Barcelona

Spain

Last review date of this leaflet:November 2024

The detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.es/